Monthly Archives: November 2020
KRAS is a commonly mutated gene across solid tumors, thus makes it a potential target for anti-tumor drugs. Recently, some developing drugs showed potential in treating the KRAS G12C mutant.
KRAS is the first human oncogene discovered in 1983; however, no any approved KRAS target therapy till now. The challenges are protein itself lack of known allosteric regulatory sites and binding affinity to GTP/GDP, thus directly targeting oncogenic KRAS with small molecules in the nucleotide-binding site has been difficult.
Breast cancer is the most common cancer in women. Hormone therapy is the major treatment option for patients with estrogen receptor-positive (ER+) and Her2-negative (Her2-) breast cancer.
◼ ACE1702 demonstrates enhanced cytotoxicity against multiple HER2-expressing cell lines and activity under immunosuppressive conditions
◼ ACE1702 maintains activity following cryopreservation
◼ oNK cell expression profiling reveals high levels of activating receptors and low levels of inhibitory receptors
LAGUNA HILLS, CA, November 07, 2020 Arthrosi Therapeutics, a clinical stage biopharmaceutical company focused on developing a best in class treatment for gout, has completed a Phase 2a clinical trial for company’s lead asset, AR882. Results from two cli nical studies of AR882 conducted at Australia and New Zealand were presented in Annual meeting of American College of Rheumatology Convergence 2020. AR882 demonstrated a strong safety profile, favorable pharmacokinetics, pharmacodynamics, and efficacy outcome in healthy volunteers and in gout patients.
Patients with chronic gout (serum urate (sUA ) baseline 9.0 mg/dL) were treated with AR882 50 mg in the phase 2a study, 95% of patients showed sUA levels below 6 mg/dL and 5 mg/dL throughout the entire day. The results indicate that AR882 considerably outperformed the current frontline therapies for gout and has potential to provide clinical benefit in hyperuricemia and gout patients. A phase 2b study for AR882 is being planned. In addition, Arthrosi’s oncology candidate will also start IND enabling studies with plans to submit the US IND at H2 2021.
Gout has a huge market. In China, there are 200 million hyperuricemia patients and nearly 20 million gout patients while the United States has 120 million hyperuricemia patients and 12 million gout patients,” said Litain Yeh, Arthrosi’s CEO,” At Arthro si, we are committed to the independent development of new drugs to address the unmet medical needs in the treatment for gout. We expect our drug to be the most effective and safe treatment to reduce the frequency of gout attacks and dissolve tophi. Eventu ally, Arthrosi’s treatment will become the first line medication for gout treatment.”
Our leadership team is comprised of key functional experts who have tremendous experience with the FDA’s drug approval process,” continued Dr. Yeh, “We have a range of successful preclinical and clinical trials as well as global approvals already under our belts. The team consists of the core scientists who did the research, management, and development of Lesinurad.
Arthrosi recently completed a series C financing rou nd led by LH Ventures to facilitate the next stage of its clinical trials. Along with other biotech investors, HEDA Ventures participated in this financing round. HEDA Ventures will continue to support Arthrosi’s ongoing efforts to advance the next generat ion of gout and oncology treatments.
About Arthrosi Therapeutics
Arthrosi is a clinical stage biopharmaceutical company, developing an oral, best in class treatment for gout along with additional pipelines in oncology. Led by experienced management team with extensive expertise in gout and oncology drug development, Arthrosi i s developing novel therapies to address unmet medical needs in the treatments of gout, chronic kidney disease and oncology.
- 1
- 2